Ms. Iris Bincovich reports

INNOCAN PHARMA CORPORATION ANTICIPATES LISTING ON THE NYSE AMERICAN STOCK EXCHANGE WITH CONCURRENT OFFERING

Innocan Pharma Corp., further to its news release dated Jan. 2, 2026, now anticipates to list on NYSE American on or around Jan. 30, 2026, subject to approval of its listing application and continued compliance with exchange rules, subject to authorization of the application and continued compliance with the exchange rules.

In connection with the anticipated NYSE listing, Innocan is also conducting a concurrent offering of its securities, subject to market conditions and regulatory approval. Additional details regarding the offering will be provided through the company's filings with the U.S. Securities and Exchange Commission (SEC) and SEDAR+.

Innocan expects that its common shares will continue to trade on the OTC Markets' OTCQB until the close of the market on or about Jan. 29, 2026. Upon effectiveness of the listing on the NYSE American, trading of the common shares on the OTCQB will terminate. Stockholders of Innocan do not need to take any action prior to the listing of Innocan's shares on the NYSE American. Innocan's common shares will continue to trade on the Canadian Securities Exchange under the symbol INNO.

About Innocan Pharma Corp.

Innocan is an innovator in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, Innocan developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of synthetic CBD for non-opioid pain management. In the wellness sector, Innocan develops and markets a wide portfolio of high performance self-care and beauty products to promote a healthier lifestyle. Under this segment, Innocan carries on business through its 60-per-cent-owned subsidiary, BI Sky Global Ltd., which focuses on advanced, targeted on-line sales.

We seek Safe Harbor.